An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xencor to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced participation in two investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference is scheduled for November 22, 2021 at 10:00 a.m. EST. The Evercore ISI 4th Annual HealthconX Conference will take place on December 1, 2021 at 1:00 p.m. EST. Webcasts of these presentations will be available for 30 days on their website.
Positive
None.
Negative
None.
MONROVIA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:
Piper Sandler 33rd Annual Virtual Healthcare Conference Presentation Available: Monday, November 22, 2021, 10:00 a.m. EST / 7:00 a.m. PST
Evercore ISI 4th Annual HealthconX Conference Presentation Date: Wednesday, December 1, 2021, 1:00 p.m. EST / 10:00 a.m. PST
Webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the live Evercore ISI presentation will be posted on the Xencor website approximately one hour after the live event. Both presentations will be available on the website for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
